| Combination of Nilotinib (AMN107) and RAD001 in Patients With Acute Myeloid Leukemia (NCT00762632) | Technical University of Munich | 2007-12-01 |
| Clinical Factors Associated With the Development of Severe Sepsis in Patients Being Treated for Acute Myeloid Leukemia (NCT00806325) | Ohio State University | 2007-11-01 |
| A Study Evaluating the Effects of CLAG With Gleevec in Refractory or Relapsed Acute Myeloid Leukemia (NCT00594555) | University of Cincinnati | 2007-11-01 |
| Safety and Tolerability Study of Voreloxin and Cytarabine Combination in Acute Myeloid Leukemia in Humans (NCT00541866) | Sunesis Pharmaceuticals | 2007-10-06 |
| Phase I-II Study of Idarubicin, Cytarabine, and Sorafenib (BAY43-9006) (NCT00542971) | M.D. Anderson Cancer Center | 2007-10-01 |
| Cytarabine in Combination With Arsenic Trioxide vs. Cytarabine Alone in Elderly Patients With Acute Myeloid Leukemia (NCT00513305) | Cephalon | 2007-10-01 |
| Efficacy of Gemtuzumab Ozogamycin for Patients Presenting an Acute Myeloid Leukemia (AML) With Intermediate Risk (NCT00860639) | Nantes University Hospital | 2007-10-01 |
| A Study of Lintuzumab (SGN-33) in Combination With Low Dose Cytarabine in Patients 60+ Years With AML (NCT00528333) | Seagen Inc. | 2007-09-01 |
| Phase I Dose-Escalation Trial of Clofarabine Followed by Escalating Doses of Fractionated Cyclophosphamide in Children With Relapsed or Refractory Acute Leukemias (NCT00852709) | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | 2007-09-01 |
| Phase 2 Haplotype Mismatched HSCT in Patients With Hematological Malignancies (NCT00593554) | Sherif S. Farag | 2007-08-07 |
| Monitoring Minimal Residual Disease of Patients With Acute Myelogenous Leukemia or High Grade Myelodysplastic Syndrome (NCT01311258) | University of Rochester | 2007-08-01 |
| Trial of PXD101 (Belinostat) in Combination With Idarubicin to Treat AML Not Suitable for Standard Intensive Therapy (NCT00878722) | Valerio Therapeutics | 2007-08-01 |
| Combination of GTI-2040 and Cytarabine in the Treatment of Refractory and Relapsed Acute Myeloid Leukemia (AML) (NCT00565058) | Aptose Biosciences Inc. | 2007-08-01 |
| Oxaliplatin, Fludarabine, and Cytarabine in Acute Myeloid Leukemia (AML) or High-Risk Myelodysplastic Syndromes (MDS) (NCT00480987) | M.D. Anderson Cancer Center | 2007-07-01 |
| Study With Intravenous Busulfan And Fludarabine Myeloablative Conditioning Regimen For HLA Identical Sibling Donor HSCT (NCT01683123) | Grupo Espanol de trasplantes hematopoyeticos y terapia celular | 2007-07-01 |
| Timed-Sequential Induction in CBF-AML (NCT00428558) | Assistance Publique - Hôpitaux de Paris | 2007-07-01 |
| Phase I Epigenetic Priming Using Decitabine With Induction Chemotherapy in AML (NCT00538876) | Weill Medical College of Cornell University | 2007-07-01 |
| Treosulfan-based Conditioning for Transplantation in AML/MDS (NCT00491634) | Dr. Avichai Shimoni MD | 2007-06-01 |
| Modified-FLAI Induction and Consolidation Chemotherapy in Elderly Patient With Acute Myeloid Leukemia (AML) (NCT01247493) | Seoul National University Hospital | 2007-06-01 |
| Intermittent Liposomal Amphotericin B Primary Prophylaxis (NCT00451711) | Bayside Health | 2007-05-01 |
| Lenalidomide in Acute Leukemias and Chronic Lymphocytic Leukemia. (NCT00466895) | Leslie Andritsos | 2007-04-01 |
| Collecting and Storing Tissue From Young Patients With Cancer (NCT00898755) | Children's Oncology Group | 2007-03-05 |
| Study to Assess the Safety, Tolerability, and Efficacy of Tipifarnib Plus Bortezomib in the Treatment of Acute Myeloid Leukemia (NCT00510939) | University of Bologna | 2007-03-01 |
| Intraosseous Infusion of Unrelated Cord Blood Grafts (NCT00967525) | Emory University | 2007-03-01 |
| A Safety and Tolerability Extension Trial Assessing Repeated Dosing of Anti-KIR (1-7F9) Human Monoclonal Antibody in Patients With Acute Myeloid Leukaemia (NCT01256073) | Innate Pharma | 2007-02-01 |
| A Phase I Study of AC220 in Patients With Relapsed/Refractory Acute Myeloid Leukemia Regardless of FLT3 Status (NCT00462761) | Daiichi Sankyo | 2007-01-01 |
| Structural Imaging and Cognitive Functions in Adult Stem Cell Transplant Recipients Treated With Chemotherapy Alone or in Combination With Radiotherapy (NCT00606216) | Memorial Sloan Kettering Cancer Center | 2007-01-01 |
| Standard Idarubicin and Cytarabine for the Treatment of Acute Myeloid Leukemia (AML) (NCT00422591) | M.D. Anderson Cancer Center | 2006-12-01 |
| Decitabine as Maintenance Therapy After Standard Therapy in Treating Patients With Previously Untreated Acute Myeloid Leukemia (NCT00416598) | National Cancer Institute (NCI) | 2006-11-15 |
| A Study of Clofarabine for Older Patients With Newly Diagnosed Acute Myelogenous Leukemia (AML) (CLASSIC II) (NCT00373529) | Genzyme, a Sanofi Company | 2006-10-01 |
| Autologous Cytokine-induced Killer Cell Adoptive Immunotherapy for Acute Myeloid Leukemia and Myelodysplastic Syndrome (NCT00394381) | Singapore General Hospital | 2006-10-01 |
| Chronic Graft-versus-host Disease (cGvHD) Prophylaxis With or Without ATG Prior to Stem Cell Transplantation (SCT) From HLA-identical Siblings in Patients With Acute Leukemia (NCT00678275) | Universitätsklinikum Hamburg-Eppendorf | 2006-10-01 |
| Efficacy of Sorafenib Added to Standard Primary Therapy in Elderly Patients With Newly Diagnosed AML (NCT00373373) | University Hospital Muenster | 2006-09-01 |
| Study to Assess the Safety of Escalating Doses of AT9283, in Patients With Leukemias (NCT00522990) | Astex Pharmaceuticals, Inc. | 2006-09-01 |
| Allogeneic Cytokine-induced Killer Immunotherapy for Relapse After Allogeneic Marrow Transplant for Haematological Malignancies (NCT00460694) | Singapore General Hospital | 2006-08-01 |
| DNR and AraC Combined to Fractionated Mylotarg® in Patients With First Relapse of AML (NCT02182596) | Acute Leukemia French Association | 2006-06-01 |
| Safety, Efficacy and Pharmacokinetics of an Antifungal in Patients Undergoing Chemotherapy (NCT00413439) | Basilea Pharmaceutica | 2006-05-01 |
| Study of XL999 in Patients With Acute Myeloid Leukemia (AML) (NCT00322673) | Symphony Evolution, Inc. | 2006-05-01 |
| Safety and Anti-Disease Activity of CHR-2797 (Tosedostat) in Elderly and/or Treatment Refractory Patients With Acute Myeloid Leukemia (AML) and Multiple Myeloma (MM) (NCT00689000) | Chroma Therapeutics | 2006-05-01 |
| Microtransplantation in Older Patients With Acute Myeloid Leukemia (NCT02831192) | The Affiliated Hospital of the Chinese Academy of Military Medical Sciences | 2006-05-01 |
| Nebulized Liposomal Amphotericin B Ambisome for Prophylaxis of Invasive Pulmonary Aspergillosis (NCT00391014) | PETHEMA Foundation | 2006-01-01 |
| Study of Immune Response Modifier in the Treatment of Hematologic Malignancies (NCT00276159) | Masonic Cancer Center, University of Minnesota | 2006-01-01 |
| High-dose Cytarabine and Survival in AML (NCT01034839) | University of Sao Paulo General Hospital | 2006-01-01 |
| Umbilical Cord Blood Transplant, Cyclophosphamide, Fludarabine, and Total-Body Irradiation in Treating Patients With Hematologic Disease (NCT00719888) | Fred Hutchinson Cancer Center | 2005-11-18 |
| Dasatinib as Therapy for Myeloproliferative Disorders (MPDs) (NCT00255346) | M.D. Anderson Cancer Center | 2005-11-15 |
| Treatment of Hematologic Malignancies With Single-Unit or Double-Unit Cord Blood Transplantation (NCT00328237) | Colorado Blood Cancer Institute | 2005-11-01 |
| A Safety Study of Lintuzumab in Patients With Acute Myeloid Leukemia and Myelodysplastic Syndrome (NCT00283114) | Seagen Inc. | 2005-11-01 |
| Trial of Decitabine in Patients With Acute Myeloid Leukemia (NCT00260832) | Eisai Inc. | 2005-11-01 |
| Natural Killer (NK) Cell Transplantation for AML (NCT00187096) | St. Jude Children's Research Hospital | 2005-09-01 |
| Stem Cell Transplantation as Immunotherapy for Hematologic Malignancies (NCT00143559) | St. Jude Children's Research Hospital | 2005-08-01 |
| Amonafide in Combination With Cytarabine in Secondary AML (NCT00273884) | Xanthus Pharmaceuticals, Inc. | 2005-08-01 |
| Myeloablative Umbilical Cord Blood Transplantation in Hematological Diseases (NCT00309842) | Masonic Cancer Center, University of Minnesota | 2005-07-28 |
| Combination 5-azacitidine and Gemtuzumab Ozogamicin Therapy for Treatment of Relapsed Acute Myeloid Leukemia (AML) (NCT00766116) | University of California, San Diego | 2005-07-01 |
| Rapamycin in Combination With Low-dose Aracytin in Elderly Acute Myeloid Leukemia Patients (NCT00235560) | University Hospital, Toulouse | 2005-06-01 |
| IV Busulfan With Allo-BMT: Study for Patients With Acute Myelogenous Leukemia and Myelodysplastic Syndrome (NCT00469144) | M.D. Anderson Cancer Center | 2005-06-01 |
| T-cell Depleted Donor Lymphocyte Infusion (DLI)for Acute Myeloid Leukemia (AML) or High Risk Myelodysplastic Syndrome (MDS) (NCT00242515) | National University Hospital, Singapore | 2005-03-01 |
| Study of Decitabine for Treatment of Older Patients With Acute Myeloid Leukemia (AML) (NCT00358644) | Eisai Inc. | 2005-03-01 |
| FLAG+Ida With G-CSF Priming for Patients Younger Than 60 Years With Resistant AML (NCT00559221) | Cooperative Study Group A for Hematology | 2004-12-01 |
| Fludarabine and Cytarabine as Continuous Infusion Plus G-CSF Priming for Elderly Patients With Resistant AML (NCT00529880) | Cooperative Study Group A for Hematology | 2004-12-01 |
| MS-275 and Azacitidine in Treating Patients With Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia, or Acute Myeloid Leukemia (NCT00101179) | National Cancer Institute (NCI) | 2004-11-03 |
| Gemtuzumab Ozogamicin Before Allogeneic Stem Cell Transplantation (NCT00460447) | University Hospital Carl Gustav Carus | 2004-10-01 |
| Phase 3 Trial for AML Patients in CR2 Comparing 8Gy TBI /Fludarabine to Conditioning With TBI 12Gy/Cyclophosphamide (NCT00125606) | University Hospital Muenster | 2004-10-01 |
| Safety, Pharmacokinetics and Pharmacodynamics of TKI258 in Subjects With Acute Myeloid Leukemia (NCT00279773) | Novartis Pharmaceuticals | 2004-09-01 |
| Pilot Study of Reduced-Intensity Umbilical Cord Blood Transplantation in Adult Patients Wtih Advanced Hematopoietic Malignancies (NCT00513318) | University of California, San Francisco | 2004-08-01 |
| To Determine the Role of Adding Campath-1H or ATG Given In-vivo in Addition to Fludarabine and Low Dose Busulfex on Outcome in Patients Treated With Reduced Intensity Conditioning (NCT00226512) | Hadassah Medical Organization | 2004-07-01 |
| Study Evaluating the Addition of Amifostine (Ethyol®) to Idarubicin and Cytosine Arabinoside in Older Patients With Acute Myeloid Leukemia (NCT00086099) | MedImmune LLC | 2004-07-01 |
| Clofarabine vs Clofarabine in Plus With Low-Dose Ara-C in Previously Untreated Patients With Acute Myeloid Leukemia (AML) and High-Risk Myelodysplastic Syndromes (MDS). (NCT00088218) | M.D. Anderson Cancer Center | 2004-07-01 |
| Study on All-Trans Retinoic Acid, Induction and Consolidation Therapy, and Pegfilgrastim After Consolidation Therapy in Younger Patients With Newly Diagnosed Acute Myeloid Leukemia (NCT00151242) | University of Ulm | 2004-07-01 |
| A Study of Clofarabine in Older Patients With Acute Myeloid Leukemia (AML) for Whom Chemotherapy Is Not Suitable (NCT00924443) | Genzyme, a Sanofi Company | 2004-06-01 |
| All-Trans Retinoic Acid in Combination With Standard Induction and Consolidation Therapy in Older Patients With Newly Diagnosed Acute Myeloid Leukemia (NCT00151255) | University of Ulm | 2004-06-01 |
| HLA-Nonidentical Stem Cell and Natural Killer Cell Transplantation for Children Less the Two Years of Age With Hematologic Malignancies (NCT00145626) | St. Jude Children's Research Hospital | 2004-05-01 |
| Allogenic Stem Cell Transplantation in Patients With High Risk CD33+ AML/MDS/JMML (NCT00669890) | New York Medical College | 2004-05-01 |
| HLA-mismatched MST vs HLA-matched NST for AML in Intermediate-risk (NCT02461121) | The Affiliated Hospital of the Chinese Academy of Military Medical Sciences | 2004-05-01 |
| Infusion of Specially Treated Umbilical Cord Stem Cells After Chemoradiation Treatment for Blood Cancers (NCT00089596) | ViaCell | 2004-03-01 |
| Tipifarnib Versus Best Supportive Care in the Treatment of Newly Diagnosed Acute Myeloid Leukemia (AML) (NCT00093990) | Johnson & Johnson Pharmaceutical Research & Development, L.L.C. | 2004-01-01 |
| NOPHO-AML 2004 Study for Children With Acute Myeloid Leukemia (NCT00476541) | University of Aarhus | 2004-01-01 |
| Study of Clofarabine & Cytosine Arabinoside Therapy for Older Adults With Acute Myeloid Leukemia (NCT00081822) | University of Alabama at Birmingham | 2004-01-01 |
| Study of Bexarotene in Patients With Acute Myeloid Leukemia (NCT00316030) | Abramson Cancer Center at Penn Medicine | 2004-01-01 |
| Reduced Intensity Conditioning Transplantation Versus Standard of Care in Acute Myeloid Leukemia (NCT00342316) | Vastra Gotaland Region | 2003-12-18 |
| Standard vs. Reduced-Intensity Conditioning in Patients With Acute Myeloid Leukemia in First Remission (NCT00150878) | University Hospital Carl Gustav Carus | 2003-12-01 |
| Clofarabine Combinations in Relapsed/Refractory Acute Myeloid Leukemia (AML), Myelodysplastic Syndromes (MDS) and Myeloid Blast Phase Chronic Myeloid Leukemia (CML) (NCT00067028) | M.D. Anderson Cancer Center | 2003-12-01 |
| Study of CEP-701 (Lestaurtinib) in Patients With Acute Myeloid Leukemia (AML) (NCT00079482) | Cephalon | 2003-10-01 |
| Mylotarg and Ara-C in Untreated Patients Above 60 Years With AML and High-Risk MDS (NCT00195000) | Weill Medical College of Cornell University | 2003-05-01 |
| Fludarabine, Cytarabine, Topotecan in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia (NCT00488709) | PETHEMA Foundation | 2003-05-01 |
| Pentostatin and Lymphocyte Infusion in Preventing Graft Rejection in Patients Who Have Undergone Donor Stem Cell Transplant (NCT00096161) | Fred Hutchinson Cancer Center | 2003-05-01 |
| High-dose Cytarabine/Mitoxantrone Followed by Autotransplantation for t-MDS/t-AML (NCT00774046) | University of Chicago | 2002-12-01 |
| Pilot Study of Umbilical Cord Blood Transplantation in Adult Patient With Advanced Hematopoietic Malignancies (NCT00514722) | University of California, San Francisco | 2002-10-01 |
| Early Allogeneic Blood Stem Cell Transplantation in High-risk Acute Myeloid Leukemia (AML) (NCT00188136) | University Hospital Carl Gustav Carus | 2002-08-01 |
| A Randomized Trial of Human Growth Hormone (hGH) vs Placebo in Intensively Treated Haemato-Oncology Patients. (NCT00300664) | Royal Marsden NHS Foundation Trust | 2002-07-01 |
| Study of Tipifarnib as Postconsolidation Therapy for Acute Myeloid Leukemia in Patients 60 Years and Older (NCT00048503) | Johnson & Johnson Pharmaceutical Research & Development, L.L.C. | 2002-06-01 |
| WT1 Peptide Vaccination in Acute Myeloid Leukemia (AML) (NCT00153582) | Charite University, Berlin, Germany | 2002-04-01 |
| Treatment of Children and Adolescents With Refractory or Relapsed Acute Myeloid Leukemia (NCT00186966) | Dutch Childhood Oncology Group | 2002-03-01 |
| PKC412 in Participants With Acute Myeloid Leukemia or With Myelodysplastic Syndrome (CPKC412A2104 Core); and PKC412 in Participants With Acute Myeloid Leukemia or With Myelodysplastic Syndrome With Either Wild Type or Mutated FMS-like Tyrosine Kinase 3 (FLT3) (CPKC412A2104E1 and CPKC412A2104E2) (NCT00045942) | Novartis Pharmaceuticals | 2002-01-30 |
| Non-Myeloablative Allogeneic Stem Cell Transplantation With Matched Unrelated Donors for Treatment of Hematologic Malignancies, Renal Cell Carcinoma, and Aplastic Anemia (NCT00513175) | University of California, San Francisco | 2001-10-01 |
| Study Evaluating Mylotarg (Gemtuzumab Ozogamicin) in Usual Care (NCT00161668) | Wyeth is now a wholly owned subsidiary of Pfizer | 2001-10-01 |
| Dose Escalation Phase I/II Study of Lovastatin With High-Dose Cytarabine for Refractory or Relapsed AML (NCT00583102) | University of Iowa | 2001-06-01 |
| Sorafenib In Relapse of FMS-like Tyrosine Kinase 3 (FLT3)-Internal Tandem Duplication (ITD) AML Trial (NCT02867891) | Robert Zeiser | 2001-03-01 |
| Prospective Randomized Study Comparing One or Two High Dose Chemotherapy Regimen Followed by Autologous Stem Cell Transplantation (NCT01015196) | Nantes University Hospital | 2001-01-01 |
| Study Evaluating Gemtuzumab Ozogamicin in Acute Myeloid Leukemia (NCT00037596) | Wyeth is now a wholly owned subsidiary of Pfizer | 2000-08-01 |
| T Cell Depletion for Recipients of HLA Haploidentical Related Donor Stem Cell Grafts (NCT00368355) | Baylor College of Medicine | 2000-04-01 |